GlobeNewswire Clinical StudiesOriginal article
Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients
Phase 1positiveNovoBioJectPositive
AI Analysis
Summary
Amplio Pharma reported positive Phase 1b results for NovoBioJect, which increased active methotrexate in immune cells of rheumatoid arthritis patients by 38%. Phase 2a is planned for 2027.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
NovoBioJect increased active methotrexate in immune cells of rheumatoid arthritis patients by 38%
Importance:6/10
Sentiment:
0.70
Phase 1bRheumatoid ArthritisClinical DataMethotrexate
Read the original article
Published by GlobeNewswire Clinical Studies on October 1, 2026 1:53 PM